imugene investor webinar | fda ind clearance for oncarlytics
Published 1 year ago • 1.7K plays • Length 23:29Download video MP4
Download video MP3
Similar videos
-
18:05
investor webinar – imugene limited (asx:imu) & kincell bio strategic partnership investor webinar
-
4:14
imugene (asx:imu) doses first patient in iv arm of phase 1 oncarlytics trial targeting solid cancers
-
33:41
imugene investor webinar | acquisition of license for azer-cel cell therapy
-
26:56
investor presentation post asx news: imugene and eureka therapeutics oncarlytics collaboration
-
7:40
imugene limited (asx: imu) emergence 2024: presentation by leslie chong, managing director and ceo
-
4:53
imugene featured on fox business's 'trending today' as a trailblazer in the biotechnology industry.
-
6:37
leslie chong discusses imugene's strategic partnership with kincell bio | ausbiz interview
-
3:55
the journey of a medicine: from production to delivery to patients
-
5:40
imugene secures ind approval for first-in-class oncarlytics trial
-
4:45
leslie chong's first interview following our news imugene secured two fda ind approvals
-
15:06
imugene (asx:imu) | jmm & éthica capital innovation & investment insights | may 2024
-
4:30
imugene md shares with juststocks plans for phase 1 oncarlytics combination study
-
4:30
imugene's cf33 vaxinia granted fda fast track designation
-
6:16
imugene's new cancer therapy cd19 (oncarlytics) considered the 'holy grail'
-
2:59
imugene: a worldwide license to attack blood cancer
-
5:33
imugene ceo says fda ind approval for pd1-vaxx is 'huge news' for the company
-
18:10
asx ceo connect march 2023 imugene limited (asx: imu)
-
5:04
imugene (asx:imu) | jmm & éthica capital innovation interview \ may 2024